ETON --3x FDA Decisions: July & October 2019 , May 2020 Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ETON --3x FDA Decisions: July & October 2019 , May 2020

ETON 18.20

-0.4%

Oct 30 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: BioHero	7/1/2019 9:50:59 AM
	of 16

First FDA Decision in 10 Days if approved stock likely to jump above $11+ especially of its very low float .GL EM-100 Ophthalmic Solution •Innovative over-the-counter ophthalmic solution for treatment of allergic conjunctivitis •If approved, EM-100 would be the first preservative-free ophthalmic product indicated for allergic conjunctivitis •Product has been filed with the FDA and is expected to be approved in 2019 •U.S. allergic conjunctivitis ophthalmic market is >$600 million annually •Eton partnered with Bausch Health for commercialization •Eton receives additional milestone payment upon approval and a royalty on net sales

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next